Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

PURPOSE: To evaluate AZD4635, an adenosine A(2A) receptor antagonist, as monotherapy or in combination with durvalumab in patients with advanced solid tumors. PATIENTS AND METHODS: In phase Ia (dose escalation), patients had relapsed/refractory solid tumors; in phase Ib (dose expansion), patients ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Emerson A., Bendell, Johanna C., Falchook, Gerald S., Bauer, Todd M., Drake, Charles G., Choe, Jennifer H., George, Daniel J., Karlix, Janet L., Ulahannan, Susanna, Sachsenmeier, Kris F., Russell, Deanna L., Moorthy, Ganesh, Sidders, Ben S., Pilling, Elizabeth A., Chen, Huifang, Hattersley, Maureen M., Das, Mayukh, Kumar, Rakesh, Pouliot, Gayle P., Patel, Manish R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660540/
https://www.ncbi.nlm.nih.gov/pubmed/36044531
http://dx.doi.org/10.1158/1078-0432.CCR-22-0612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660540/
https://www.ncbi.nlm.nih.gov/pubmed/36044531
http://dx.doi.org/10.1158/1078-0432.CCR-22-0612

Ejemplares similares